Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Max Yano"'
Autor:
Janek S. Walker, Zachary A. Hing, Steven Sher, James Cronin, Katie Williams, Bonnie Harrington, Jordan N. Skinner, Casey B. Cempre, Charles T. Gregory, Alexander Pan, Max Yano, Larry P. Beaver, Brandi R. Walker, Jadwiga M. Labanowska, Nyla A. Heerema, Krzysztof Mrózek, Jennifer A. Woyach, Amy S. Ruppert, Amy Lehman, Hatice Gulcin Ozer, Vincenzo Coppola, Pearlly Yan, John C. Byrd, James S. Blachly, Rosa Lapalombella
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Some genes that are part of balanced translocations are reported as drivers for tumourigenesis. Here, the authors report a translocation involving MTCP1 in chronic lymphocytic leukemia and show that MTCP1 overexpression leads to the disease in a muri
Externí odkaz:
https://doaj.org/article/810bfd0089064a989b380ab83b7f18b0
Publikováno v:
Cancers, Vol 14, Iss 23, p 5787 (2022)
Immunotherapy approaches have advanced rapidly in recent years. While the greatest therapeutic advances so far have been achieved with T cell therapies such as immune checkpoint blockade and CAR-T, recent advances in NK cell therapy have highlighted
Externí odkaz:
https://doaj.org/article/a0048094ecef491286d213f90b9a74bd
Autor:
Max Yano, Chia Sharpe, J. Rachel Lance, Janani Ravikrishnan, Kevan Zapolnik, Xiaokui Mo, Jennifer A. Woyach, Deepa Sampath, Adam S. Kittai, Sumithira Vasu, Seema Bhat, Kerry A. Rogers, Dean A. Lee, Natarajan Muthusamy, John C. Byrd
Publikováno v:
Blood Advances. 6:5641-5654
Successes with anti-CD20 antibodies in chronic lymphocytic leukemia (CLL) and enhanced activity of Fc-engineered vs unmodified antibody therapy suggest a potentially impactful role for natural killer (NK) cells and other innate immune cells in contro
Autor:
Max Yano, Jessica Nunes, Xiaokui Mo, Kerry A. Rogers, Jennifer A. Woyach, John C. Byrd, Natarajan Muthusamy
Publikováno v:
Blood Advances. 6:5440-5448
Cytotoxic T lymphocyte antigen 4 (CTLA4) is a major immune checkpoint and target for cancer immunotherapy. Although originally discovered and primarily studied on T cells, its role on other cell types has also been recognized in recent years. Here we
Autor:
Amy S. Ruppert, Larry Beaver, Bonnie K. Harrington, Janek S. Walker, Brandi R. Walker, Katie Williams, James Cronin, Zachary A. Hing, Alexander Pan, Jordan N. Skinner, Jennifer A. Woyach, Nyla A. Heerema, Steven Sher, Amy Lehman, Charles Thomas Gregory, Vincenzo Coppola, Rosa Lapalombella, Krzysztof Mrózek, Max Yano, Pearlly S. Yan, Hatice Gulcin Ozer, James S. Blachly, Jadwiga Labanowska, John C. Byrd, Casey Cempre
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications
Nature Communications
Rare, recurrent balanced translocations occur in a variety of cancers but are often not functionally interrogated. Balanced translocations with the immunoglobulin heavy chain locus (IGH; 14q32) in chronic lymphocytic leukemia (CLL) are infrequent but
Autor:
Adam S. Kittai, Ying Huang, Kyle A. Beckwith, Seema A. Bhat, David A. Bond, John C. Byrd, Daniel Goldstein, Michael R. Grever, Cecelia Miller, Kerry A. Rogers, Max Yano, Jennifer A. Woyach
Publikováno v:
American journal of hematologyREFERENCES.
Chronic lymphocytic leukemia (CLL) transformation to aggressive lymphoma, known as Richter's Transformation (RT), has a dismal prognosis. There are limited data evaluating risk of RT in patients treated with ibrutinib. We performed a retrospective an
Autor:
John C. Byrd, Frank Frissora, Kevan Zapolnik, Xiaokui Mo, Mary K. McKenna, Minh Tran, Rahul Ramaswamy, Vivek M. Rangnekar, Rajeswaran Mani, Ronni Wasmuth, Bonnie K. Harrington, Subbarao Bondada, Joseph T. Greene, Natarajan Muthusamy, Max Yano
Publikováno v:
Blood Advances. 3:1255-1266
Prostate apoptosis response 4 (Par-4) is a tumor suppressor that prevents proliferation and induces cell death in several solid tumors. However, its role in B-cell malignancies has not been elucidated. To describe the role of Par-4 in chronic lymphoc
Autor:
John C. Byrd, Amy S. Ruppert, Katie Williams, Casey Cempre, Steven Sher, James S. Blachly, Brandi R. Walker, James Cronin, Jennifer A. Woyach, Amy Lehman, Charles Thomas Gregory, Zachary A. Hing, Nyla A. Heerema, Janek S. Walker, Vincenzo Coppola, Krzysztof Mrózek, Bonnie K. Harrington, Hatice Gulcin Ozer, Max Yano, Jordan N. Skinner, Rosa Lapalombella, Jadwiga Labanowska, Larry Beaver
Publikováno v:
Cancer Research. 81:2260-2260
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in Western countries and is spelled by substantial genetic and clinical heterogeneity. During CLL transformation, loss or gain of genetic material appears to be a key determinant
Publikováno v:
Blood. 134:4303-4303
Introduction: While treatments for CLL have improved in recent years, CLL remains incurable for most patients who often rely on long-term suppressive medications. These can present complications associated with undesirable side effects and the risk o
Publikováno v:
Blood. 134:4302-4302
Introduction: While treatments for CLL have improved in recent years, CLL remains incurable for most patients who often rely on long-term suppressive medications. These can present complications associated with undesirable side effects and the risk o